Published on:
    Journal of Cardiovascular Disease Research, 2013; 4(3):187-190
    Clinical Case Reports Based Study | doi:10.1016/j.jcdr.2013.08.005

    The potential contribution of ranolazine to Torsade de Pointe

    Authors:

    Zhigang Liu, Richard B. Williams, Boaz D. Rosen*

    Department of Medicine, MedStar Harbor Hospital, Baltimore, MD 21225, USA.

    Abstract:

    Ranolazine is a novel anti-anginal agent acting through pharmacologic mechanism of inhibition of the late phase of the inward sodium current. In addition, it is a potent inhibitor of rapid delayed rectifier potassium currents, leading to prolongation of the QT interval. However, ranolazine has not yet described to be associated with Torsade de Pointes despite its QT-prolonging effect. In this case report, we describe a patient on ranolazine who developed Torsade de Pointes and discuss about the potential contribution of ranolazine to the development of Torsade de Pointes.

    Key words: Ranolazine, Prolonged QT interval, Torsade de Pointes.